Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 603-612

  Snoeck, E ^a   Piotrovskij, V ^a   Jacqmin, P ^a   Van Peer, A ^a   Danhof, M ^b   Ver Donck, K ^a   Woestenborghs, R ^a   Van Belle, H ^a   Van Bortel, L ^c   Van Gool, R ^a   Dupont, A G ^a   Heykants, J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b LEIDEN UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adenosine breakdown; Draflazine; Inhibition; Non linear red blood cell partitioning; Nucleoside transport inhibitor; Pharmacodynamics; Pharmacokinetics; Population analysis; Red blood cell occupancy

Indexed keywords

DRAFLAZINE; NUCLEOSIDE TRANSPORT INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING KINETICS; CELL SEPARATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; ERYTHROCYTE KINETICS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NUCLEOSIDE TRANSPORT; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION ANALYSIS; RECEPTOR OCCUPANCY;

EID: 8544276566     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00593.x     Document Type: Article

References (31)

1. 2. J Mol Cell Cardiol 1991; 23: 495-504.
2. Van Belle H. Specific metabolically active anti-ischemic agents: adenosine and nucleoside transport inhibitors. In Cardiovascular pharmacology and therapeutics, eds Singh et al., New York: Churchill Livingstone, 1994; 217-235.
3. Belardmelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32: 73-97.
4. Schrader J. Adenosine. A homeostatic metabolite in cardiac energy metabolism. Circulation 1990; 81: 389-391.
5. Engler RL. Adenosine. The signal of life? Circulation 1991; 84: 951-955.
6. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischaemia. Circulation 1992; 85: 893-904.
7. Schrader WP, West CA. Localization of adenosine deaminase and adenosine deaminase complexing protein in rabbit heart. Circ Res 1990; 66: 754-762.
8. Van Belle H. Uptake and deamination of adenosine by blood: species differences, effect of pH, ions, temperature and metabolic inhibitors. Biochem Biophys Acta 1969; 192: 124-132.
9. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine. Cardiovasc Res 1993; 27: 68-76.
10. Van Belle H. Nucleoside transport inhibition for cardioprotection: new perspectives for the clinic. Drug Dev Res 1993; 28: 344-348.
11. Van Belle H, Janssen PAJ. Comparative pharmacology of nucleoside transport inhibitors. Nucleosides and Nucluetides 1991; 10: 975-982.
12. Van Belle H, Wynants J, Ver Donck K. Comparison of the existing transport inhibitors: in vitro and in vivo data. In Purine and pyrimidine metabolism in man VII, Part A, eds. Harkness RA, et al., New York: Plenum Press, 1991: 419-422.
13. Van Belle H, Verheyen W, Ver Donck K, Janssen PAJ, Robertson JIS. Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor. J Cardiovasc Pharmacol 1992; 20: 173-178.
14. Van Belle H, Ver Donck K, Verheyen W. Role of nucleoside transport inhibition and endogenous adenosine in the prevention of catecholamine induced death in rabbits. Cardiovasc Res 1993; 27: 111-115.
15. Masuda M, Sukehiro S, Möllhoff T, Van Belle H, Flameng W. Effect of nucleoside transport inhibition on adenosine and hypoxanthine accumulation in the ischemic human myocardium. Arch Int Pharmacodyn 1991; 322: 45-54.
16. Masuda M, Demeulemeester A, Chang-Chun C, Hendrikx M, Van Belle H, Flameng W. Cardioprotective effects of nucleoside transport inhibition in rabbit hearts. Ann Thotac Surg 1991; 52: 1300-1305.
17. Itoya M, Miura T, Sakamoto J, Urabe K, Imura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 1994; 24: 846-852.
18. Snoeck E, Jacqmin P, Van Peer A, et al. The implications of non linear red blood cell partitioning on the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. Br J Clin Pharmacol 1996; 42: 605-613.
19. Beukers MW, Kerkhof CJM, Ijzerman AP, Soudijn W. Nucleoside transport inhibition and platelet aggregation in human blood: R75251 and its enantiomers draflazine and R88016. Eur J Pharmacol 1994; 266: 57-62.
20. Böhm M, Weinhold C, Schwinger RHG, et al. Studies of the nucleoside transport inhibitor, draflazine, in the human myocardium. Br J Pharmacol 1994; 112: 137-142.
21. Van Bocxlaer J. HPLC-UV method for the determination of draflazine in plasma, whole blood and animal tissues. Janssen Research Foundation, Unpublished report N106731, 1994.
22. Woestenborghs R. A specific red blood cell binding assay for the determination of draflazine in plasma. Janssen Research Foundation, Unpublished report N106999, Beerse, 1994.
23. Wainwright CL, Parratt JR, Van Belle H. The antiarrhythmic effects of the nucleoside transporter inhibitor, R75251, in anaesthetized pigs. Br J Pharmacol 1993; 109: 592-599.
24. Wynants J, Van Belle H. Single-run high performance liquid chromatography of nucleotides, nucleosides and major purine bases and its application to different tissue extracts. Annal Biochem 1985; 144: 258-264.
25. Wynants J, Petrov B, Nyhof J, Van Belle H. Optimization of a HPLC method for the determination of nucleosides and their catabolites. J Chromatogr 1987; 386: 297-308.
26. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977; 5: 445-479.
27. Beal SL, Sheiner LB, eds. NONMEM users guide. NONMEM Project Group. San Francisco: University of California at San Fransisco, 1989.
28. Pickard MA, Brown RR, Paul B, Paterson ARP. Binding of the nucleoside transport inhibitor 4-nitrobenzylthioinosine to erythrocyte membranes. Can J Biochem 1973; 51: 666-672.
29. Cass CE, Gaudette LA, Paterson ARP. Mediated transport of nucleosides in human erythrocytes. Specific binding of the inhibitor nitrobenzylthioinosine to nucleoside transport sites in erythrocyte membrane. Biochem Biophys Acta 1974; 345: 1-10.
30. Jarvis SM, Hammond JR, Paterson ARP, Clanachan AS. Nucleoside transport in human erythrocytes: a simple carrier with directional symmetry in fresh cells, but with directional asymmetry in cells from outdated blood. Biochem J 1983; 210: 457-461.
31. Snoeck E, Jacqmin P, Van Peer A, et al. Pharmacokinetics-pharmacodynamics and erythrocyte nucleoside transporter occupancy of draflazine. Pharm World Sci 1995; 17(suppl D): D3.